Document is current

Article History

Received: 11 March 2026

Accepted: 31 July 2026

First Online: 20 August 2026

Ethics

Competing interests: Related to this work, the German Center for Neurodegenerative Diseases (DZNE) has filed a patent application describing AChR CAAR T cells for the treatment of MG, on which H.P., S.M.R., N.v.W. and M.H. are named as inventors (PCT/EP2021/087201). G.S. has received public speaking honoraria and/or consultation fees from Argenx, Alexion, and AMGEN. M.S. is employee of EPO GmbH. V.D. has received public speaking honoraria and compensation for advisory boards and/or consultations fees from UCB, Alexion, Dianthus, Roche, Argenx, and Amgen. She declares no competing interest regarding this manuscript. K.C.O. has received research support from Argenx, Seismic Therapeutic, and Viela Bio (now Horizon Therapeutics/Amgen). K.C.O. is an equity shareholder of Cabaletta Bio. K.C.O. serves on advisory boards for Merck (EMD Serono), Neurocrine Biosciences, and Seismic Therapeutic, and has received speaking fees from Amgen, argenx, and Immunovant. A.M. received speaker or consultancy honoraria or financial research support (paid to his institution) from Alexion Pharmaceuticals, Argenx, Amgen, Axunio, Desitin, Grifols, Janssen, Merck, Novartis, Octapharma, Sanofi and UCB. He serves as member of the medical advisory board of the German Myasthenia Gravis Society (DMG e.V.) and chairman of the Association for Research in Myasthenic Syndromes in Germany (VEMSID e.V.). All other authors (S.W., H.C.K., A.K., L.Y.L., M.H., S.B., M.S., D.S., A.P., N.S., T.D., and M.P.) declare that they have no competing interests.